Clinical Value of [68Ga]Ga-FAPI-46 PET/CT Versus [18F]FDG PET/CT for Primary Staging of Gastroesophageal Adenocarcinoma: Results from a Prospective Northern European Trial.
Previous studies have demonstrated promising results for radiolabeled fibroblast activation protein inhibitor (FAPI) PET/CT in gastric cancer (GC) when compared with [18F]FDG PET/CT. In this prospective clinical trial, we assessed the impact of [68Ga]Ga-FAPI-46 PET/CT compared with [18F]FDG PET/CT and contrast-enhanced...